Migraine – Ipsen CLIN-10200-454
Participating in a clinical trial with Profound means making a real difference in the lives of others facing similar health challenges.
A migraine is a headache with severe throbbing pain or a pulsating sensation, usually on one side of the head. It is often accompanied by feeling or being sick and a sensitivity to bright lights and sound. Migraines are caused by a series of events when the brain gets stimulated or activated, which causes the release of chemicals that cause pain. IPN10200 is a medication that stops the release of these chemical messengers.
Inclusion Criteria:
- Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF. Participant has provided written informed consent and signed privacy/data protection documentation;
- Male or female ≥18 to 80 years of age at the time of signing the informed consent;
- Diagnosis of either EM or CM, per ICHD-3 criteria, for at least 12 months prior to the screening visit;
- Diagnosis of migraine at ≤50 years of age;
- Participants in the EM group: History of EM diagnosis and headache frequency (i.e. migraine and non-migraine headache): ≤14 headache days in the 4 weeks prior to randomization on study Day 1 based on information recorded in the eDiary; migraine frequency: ≥6 migraine days in the 4 weeks prior to randomization on study Day 1 based on information recorded in the eDiary;
- Participants in the CM group: History of CM diagnosis and headache frequency (i.e. migraine and non-migraine headache): ≥15 headache days in the 4 weeks prior to randomization on study Day 1 based on information recorded in the eDiary; migraine frequency: ≥8 migraine days in the 4 weeks prior to randomization on study Day 1 based on information recorded in the eDiary;
- Participant with a history of use of at least one preventive treatment for migraine.
- Other criteria may apply
Complete the form and our team will reach out soon to help determine your eligibility.
